Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RBP-7000 in Schizophrenia
NCT02768649Phase 1Completed
- Sponsor
- Indivior
- Start
- Apr 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of risperidone in schizophrenia (3 cohorts), sponsored by Indivior. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Apr 2011; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02768649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768649.